At Acceleron, we aim to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies.
Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, bone, and blood vessels. Based on this expertise, we have built a robust pipeline of biologic therapies targeted to key mechanisms underlying blood diseases and cancer.
Since our founding in 2004, Acceleron has brought multiple distinct, internally-discovered, developed and manufactured products into clinical trials, and has established collaborations with leading biopharmaceutical companies and research institutions to bring these products to the patients who need them.
RECENT RELEASES View all
EVENTS & PRESENTATIONS View allAug 6, 2015
Acceleron Q2 Earnings Call
Listen to webcast
Jun 23, 2015
JMP Securities Life Sciences Conference
Jun 15, 2015
Acceleron European Hematology Association (EHA) Congress Review
Listen to webcast
Jun 1, 2015
Jefferies 2015 Global Healthcare Conference
The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our product development strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, clinical trials and objectives of management and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates", "may", "project", "will", "would", "could" "should", "target", "continue", "intend" and similar expressions. There are a number of important factors that could cause Acceleron Pharma's actual results to differ materially from those indicated by such forward-looking statements, including the outcome of our preclinical testing and early clinical trials may not be predictive of success of later clinical trials and interim results of such clinical trials do not necessarily predict final results, the clinical drug development of our therapeutic product candidates involves a lengthy and expensive process, with an uncertain outcome, and we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our protein therapeutic product and other factors identified in the "Risk Factors" section in our filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.